MedTrace Logo

Carvedilol vs. Propranolol in Second Prophylaxis of Variceal Bleeding

NCT05651789 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2022-12-15

No results posted yet for this study

Summary

This randomized controlled trial was conducted to evaluate the efficacy and safety of carvedilol versus propranolol, combined with routine endoscopic treatment, in the secondary prophylaxis of variceal bleeding in patients with cirrhosis.

Conditions

  • Portal Hypertension
  • Varice Bleed
  • Cirrhosis, Liver

Interventions

DRUG

Carvedilol

Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 12.5mg/d. Doses are increased 3 days later. Avoid systolic blood pressure \<90 mmHg.

DRUG

Propranolol

Propranolol is started at a dose of 20 mg/d and the dose will be increased by 10 mg twice a day steps every 2-3 days until the target (heart rate: 55\~60 bpm) or to a maximum dose of 160 mg/d. Systolic arterial pressure is not less than 90 mm Hg and heart rate is not less than 50 bpm.

Sponsors & Collaborators

  • Chengdu Shangjin Nanfu Hospital

    collaborator UNKNOWN

  • West China Tianfu Hospital

    collaborator UNKNOWN

  • West China Hospital

    lead OTHER

Principal Investigators

  • Xuefeng Luo, M.D. · West China Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-31
Primary Completion
2024-12-31
Completion
2024-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05651789 on ClinicalTrials.gov